21573-08-0

Basic information

• Product Name: 2-amino-6-cyclopropylpyrimidin-4-ol
• Synonyms: 2-amino-6-cyclopropylpyrimidin-4-ol;2-amino-6-cyclopropyl-3H-pyrimidin-4-one
• CAS NO: 21573-08-0
• Molecular Formula: C7H9N3O
• Molecular Weight: 151.16586
• Mol File: 21573-08-0.mol

Chemical Properties

• Boiling Point: 302.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.65±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.99±0.50(Predicted)
• CAS DataBase Reference: 2-amino-6-cyclopropylpyrimidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-cyclopropylpyrimidin-4-ol(21573-08-0)
• EPA Substance Registry System: 2-amino-6-cyclopropylpyrimidin-4-ol(21573-08-0)

Safety Data

• Hazardous Substances Data: 21573-08-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-amino-6-cyclopropylpyrimidin-4-ol is used as a reactant for the preparation of arylpyrimidines, which are known as 5-HT2B receptor antagonists. These antagonists play a crucial role in the treatment of various medical conditions, such as migraines, gastrointestinal disorders, and psychiatric disorders, by blocking the action of serotonin on the 5-HT2B receptor.
The compound's unique structure allows it to interact with the receptor site, providing a basis for the development of new drugs with improved efficacy and reduced side effects. Its use in the pharmaceutical industry is primarily focused on the synthesis of novel therapeutic agents targeting the 5-HT2B receptor.

Upstream product

• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 50-01-1 guanidine hydrochloride 
• 593-85-1 guanidine carbonate 

Downstream Products

• 21573-09-1 4-chloro-6-cyclopropylpyrimidin-2-amine 

Relevant articles and documents

SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS

The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2, X11, X12, R1, R3, R5, R5', R6, and R7 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and/or to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Compounds of the present disclosure are especially useful for treating cancer.

Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H 4 receptor antagonists

This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS

2-Aminopyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.